MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch ...
RICHMOND, Va.--(BUSINESS WIRE)--McKesson Medical-Surgical Inc., an affiliate of the McKesson Corporation, has signed an exclusive agreement with bioMérieux, Inc. to serve the U.S. community hospital ...
DNA-Based Heat Resistant Mold Test Delivers Deeper Diagnostics in a Fraction of the Time, On-Site Solution is Now Available for Implementation Developed in partnership with historic brand Ocean Spray ...
(a) Including additions to and reversals of current provisions. (b) Corresponds to the sum of net cash from operating activities and net cash used in investing activities excluding the impact of ...
BioMerieux SA, a French maker of tests for HIV and hepatitis, said profit climbed 33 percent last year on sales of reagents for laboratory tests. Net income was 130 million euros ($168 million), ...
Consumable testing reagents account for 83% of total sales, and the closed-loop nature of BioMerieux’s diagnostic systems allows for a predictable stream of reagent sales through the full product ...
- Co-development of Assays and Co-distribution of a Fully Integrated Molecular Platform due for Launch in 2012 - bioMerieux Gains Exclusive Rights in Microbiology - bioMerieux Takes Equity Stake in ...
The NucliSENS easyMAG Magnetic Silica and NucliSENS Magnetic Extraction Reagents with distribution dates 3 May to 18 August 2016 are affected. NucliSENS easyMAG is an in vitro diagnostic (IVD)-labeled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results